<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273975</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1368</org_study_id>
    <nct_id>NCT00273975</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients</brief_title>
  <official_title>A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Trial to evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 and&#xD;
      nevirapine 4 or 7 mg/kg after 4 weeks, and efficacy and safety of the dosing when&#xD;
      administered for 48 weeks in antiretroviral drug naïve paediatric patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised open label multi-centre trial to evaluate the pharmacokinetic, efficacy and&#xD;
      safety parameters of nevirapine 150mg/m2 and nevirapine 4 or 7mg/kg when administered in&#xD;
      combination with ZDV and 3TC for 48 weeks in antiretroviral naive pediatric patients.&#xD;
&#xD;
      Primary objective: To evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2&#xD;
      in antiretroviral drug naive pediatric patients.&#xD;
&#xD;
      Secondary objective: To assess efficacy and safety of nevirapine 150 mg/m2 and nevirapine&#xD;
      4/7mg/kg after 24 and 48 weeks of treatment&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      Evaluation of recent pharmacokinetic data has suggested that a dose based on body surface&#xD;
      area rather than body weight might be a better therapeutic regimen to achieve steady state&#xD;
      plasma concentrations. The goal in this study was to determine if a Nevirapine suspension&#xD;
      dose of 150 mg/m2 BID, following a two week lead-in of 150 mg/m2 QD, produces plasma&#xD;
      nevirapine steady state concentrations of 4 - 6 ?g/mL in all age groups as was observed in&#xD;
      adult safety and efficacy trials.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      ACTG 245&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve over one dosing interval (AUCτ)</measure>
    <time_frame>1, 3 and 6 hours on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>1, 3 and 6 hours on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum observed concentration (Cmin)</measure>
    <time_frame>1, 3 and 6 hours on Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral clearance (Dose/AUC) at steady state</measure>
    <time_frame>1, 3 and 6 hours on Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-1 RNA count</measure>
    <time_frame>week 2, 4, 8, 12, 18, 24, 30, 36, 42,48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Virologic Suppression</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Virologic Failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ cell count</measure>
    <time_frame>week 2, 4, 8, 12, 18, 24, 30, 36, 42,48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ percent</measure>
    <time_frame>week 2, 4, 8, 12, 18, 24, 30, 36, 42,48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Rash</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <enrollment>123</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Male or female patients between 3 months and 16 years of age at day 28 of the study.&#xD;
&#xD;
          2. Evidence of HIV-1 infection&#xD;
&#xD;
          3. Patients who are antiretroviral drug naive&#xD;
&#xD;
          4. Plasma viral load detectable&#xD;
&#xD;
          5. CD4 &gt;=50 cells/cc3&#xD;
&#xD;
          6. Written informed permission&#xD;
&#xD;
          7. Active assent given by the patient if the child is capable of understanding the given&#xD;
             information&#xD;
&#xD;
          8. Reasonable probability for completion of the trial&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Any significant disease, other than HIV&#xD;
&#xD;
          2. Any acute illness within 2 weeks prior to Day 0&#xD;
&#xD;
          3. Patients requiring the continued use of inhibitors or inducers of P450 metabolic&#xD;
             enzymes&#xD;
&#xD;
          4. Patients requiring systematic treatment with CYP3A4 substrates&#xD;
&#xD;
          5. Patients with malabsorption, severe chronic diarrhea&#xD;
&#xD;
          6. Receipt of any cytotoxic therapy for malignancy&#xD;
&#xD;
          7. Current grade 3 or 4 clinical or laboratory toxicity&#xD;
&#xD;
          8. Pregnancy or breast-feeding&#xD;
&#xD;
          9. Females of childbearing potential not using adequate contraception. allergy or known&#xD;
             drug hypersensitivity to any of the study drugs intravenous drug abuse, alcohol or&#xD;
             substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>B.I. South Africa (Pty.) Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7900</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tygerberg</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1368_U05-2660.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 9, 2006</study_first_submitted>
  <study_first_submitted_qc>January 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2006</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

